Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hawkins

Showing results (381-390 of 580) with videos related to

Pageof 58
Sort By:
Rheumatology (Oxford, England)|May 9, 2017
Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based studyVeronika K Jaeger, Hal M Hoffman, Tom van der Poll, et al.
Blood|September 23, 2015
Natural history and outcome of light chain deposition diseaseRabya H Sayed, Ashutosh D Wechalekar, Janet A Gilbertson, et al.
British Journal of Haematology|May 10, 2017
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosisTamer Rezk, Carol J Whelan, Helen J Lachmann, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 7, 2017
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL studyElizabeth H Phillips, Stephen Nash, Toyin Adedayo, et al.
Nature|February 27, 1997
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesisD R Booth, M Sunde, V Bellotti, et al.
Blood|February 15, 2012
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survivalChristopher P Venner, Thirusha Lane, Darren Foard, et al.
British Journal of Haematology|February 21, 2025
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosisJahanzaib Khwaja, Sriram Ravichandran, Oliver Cohen, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 23, 2024
Refining prognostication in systemic AL amyloidosis: limited value of dFLCJahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, et al.
Rheumatology (Oxford, England)|May 7, 2016
Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic explorationDorota M Rowczenio, Daniela S Iancu, Hadija Trojer, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
Pageof 58

Showing results (381-390 of 580) with videos related to

Sort By:
Pageof 58
Rheumatology (Oxford, England)|May 9, 2017
Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based studyVeronika K Jaeger, Hal M Hoffman, Tom van der Poll, et al.
Blood|September 23, 2015
Natural history and outcome of light chain deposition diseaseRabya H Sayed, Ashutosh D Wechalekar, Janet A Gilbertson, et al.
British Journal of Haematology|May 10, 2017
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosisTamer Rezk, Carol J Whelan, Helen J Lachmann, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 7, 2017
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL studyElizabeth H Phillips, Stephen Nash, Toyin Adedayo, et al.
Nature|February 27, 1997
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesisD R Booth, M Sunde, V Bellotti, et al.
Blood|February 15, 2012
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survivalChristopher P Venner, Thirusha Lane, Darren Foard, et al.
British Journal of Haematology|February 21, 2025
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosisJahanzaib Khwaja, Sriram Ravichandran, Oliver Cohen, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 23, 2024
Refining prognostication in systemic AL amyloidosis: limited value of dFLCJahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, et al.
Rheumatology (Oxford, England)|May 7, 2016
Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic explorationDorota M Rowczenio, Daniela S Iancu, Hadija Trojer, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
Pageof 58